Nuclear translocation of pro-amphiregulin induces chemoresistance in gastric cancer

Cancer Science

Volumn 103, Issue 4, 2012, Pages 708-715

  Yoshida, Michihiro ^a   Shimura, Takaya ^a   Fukuda, Shinji ^b   Mizoshita, Tsutomu ^a   Tanida, Satoshi ^a   Kataoka, Hiromi ^a   Kamiya, Takeshi ^a   Nakazawa, Takahiro ^a   Higashiyama, Shigeki ^b,c   Joh, Takashi ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c EHIME UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN; CISPLATIN; FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; PACLITAXEL;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CELL MEMBRANE; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; SURVIVAL TIME; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GLYCOPROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NEOPLASM TRANSPLANTATION; PROTEIN PRECURSORS; PROTEIN TRANSPORT; STOMACH NEOPLASMS;

EID: 84858997607     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02204.x     Document Type: Article

References (33)

1. Shoyab M, Plowman GD, McDonald VL, Bradley JG, Todaro GJ. Structure and function of human amphiregulin: a member of the epidermal growth factor family. Science 1989; 243: 1074-6.
2. Rojo F, Tabernero J, Albanell J et al. Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol 2006; 24: 4309-16.
3. Kopp R, Ruge M, Rothbauer E et al. Impact of epidermal growth factor (EGF) radioreceptor analysis on long-term survival of gastric cancer patients. Anticancer Res 2002; 22: 1161-7.
4. Garcia I, Vizoso F, Martin A et al. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol 2003; 10: 234-41.
5. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37(Suppl. 4): S9-15.
6. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232.
7. Normanno N, Bianco C, De Luca A, Maiello MR, Salomon DS. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 2003; 10: 1-21.
8. Piontek M, Hengels KJ, Porschen R, Strohmeyer G. Antiproliferative effect of tyrosine kinase inhibitors in epidermal growth factor-stimulated growth of human gastric cancer cells. Anticancer Res 1993; 13: 2119-23.
9. Nanba D, Mammoto A, Hashimoto K, Higashiyama S. Proteolytic release of the carboxy-terminal fragment of proHB-EGF causes nuclear export of PLZF. J Cell Biol 2003; 163: 489-502.
10. Kinugasa Y, Hieda M, Hori M, Higashiyama S. The carboxyl-terminal fragment of pro-HB-EGF reverses Bcl6-mediated gene repression. J Biol Chem 2007; 282: 14797-806.
11. Hieda M, Isokane M, Koizumi M et al. Membrane-anchored growth factor, HB-EGF, on the cell surface targeted to the inner nuclear membrane. J Cell Biol 2008; 180: 763-9.
12. Shimura T, Kataoka H, Ogasawara N et al. Suppression of proHB-EGF carboxy-terminal fragment nuclear translocation: a new molecular target therapy for gastric cancer. Clin Cancer Res 2008; 14: 3956-65.
13. Cook PW, Pittelkow MR, Keeble WW, Graves-Deal R, Coffey RJ Jr, Shipley GD. Amphiregulin messenger RNA is elevated in psoriatic epidermis and gastrointestinal carcinomas. Cancer Res 1992; 52: 3224-7.
14. Akagi M, Yokozaki H, Kitadai Y et al. Expression of amphiregulin in human gastric cancer cell lines. Cancer 1995; 75: 1460-6.
15. Johnson GR, Saeki T, Gordon AW, Shoyab M, Salomon DS, Stromberg K. Autocrine action of amphiregulin in a colon carcinoma cell line and immunocytochemical localization of amphiregulin in human colon. J Cell Biol 1992; 118: 741-51.
16. Damstrup L, Kuwada SK, Dempsey PJ et al. Amphiregulin acts as an autocrine growth factor in two human polarizing colon cancer lines that exhibit domain selective EGF receptor mitogenesis. Br J Cancer 1999; 80: 1012-9.
17. Funatomi H, Itakura J, Ishiwata T et al. Amphiregulin antisense oligonucleotide inhibits the growth of T3M4 human pancreatic cancer cells and sensitizes the cells to EGF receptor-targeted therapy. Int J Cancer 1997; 72: 512-7.
18. Castillo J, Erroba E, Perugorria MJ et al. Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. Cancer Res 2006; 66: 6129-38.
19. Wang X, Masri S, Phung S, Chen S. The role of amphiregulin in exemestane-resistant breast cancer cells: evidence of an autocrine loop. Cancer Res 2008; 68: 2259-65.
20. Willmarth NE, Ethier SP. Amphiregulin as a novel target for breast cancer therapy. J Mammary Gland Biol Neoplasia 2008; 13: 171-9.
21. Lievre A, Laurent-Puig P. Predictive factors of response to anti-EGFR treatments in colorectal cancer. Bull Cancer 2008; 95: 133-40.
22. Ishikawa N, Daigo Y, Takano A et al. Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res 2005; 65: 9176-84.
23. Kitadai Y, Yasui W, Yokozaki H et al. Expression of amphiregulin, a novel gene of the epidermal growth factor family, in human gastric carcinomas. Jpn J Cancer Res 1993; 84: 879-84.
24. Isokane M, Hieda M, Hirakawa S et al. Plasma-membrane-anchored growth factor pro-amphiregulin binds A-type lamin and regulates global transcription. J Cell Sci 2008; 121: 3608-18.
25. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 1992; 89: 5547-51.
26. Era T, Wong S, Witte ON. Analysis of Bcr-Abl function using an in vitro embryonic stem cell differentiation system. Methods Mol Biol 2002; 185: 83-95.
27. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National cancer institute of the United States, National cancer institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
28. Xu H, Yu Y, Marciniak D et al. Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells. Mol Cancer Ther 2005; 4: 435-42.
29. Perera RM, Narita Y, Furnari FB et al. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin Cancer Res 2005; 11: 6390-9.
30. Rocha-Lima CM, Soares HP, Raez LE, Singal R. EGFR targeting of solid tumors. Cancer Control 2007; 14: 295-304.
31. Johnson GR, Saeki T, Auersperg N et al. Response to and expression of amphiregulin by ovarian carcinoma and normal ovarian surface epithelial cells: nuclear localization of endogenous amphiregulin. Biochem Biophys Res Commun 1991; 180: 481-8.
32. Modrell B, McDonald VL, Shoyab M. The interaction of amphiregulin with nuclei and putative nuclear localization sequence binding proteins. Growth Factor 1992; 7: 305-14.
33. Nylander N, Smith LT, Underwood RA, Piepkorn M. Topography of amphiregulin expression in cultured human keratinocytes: colocalization with the epidermal growth factor receptor and CD44. In Vitro Cell Dev Biol Anim 1998; 34: 182-8.